Article

bloomberg.com on 2024-01-16 15:00

Pfizer’s answer to tumbling stock is focusing on crowded cancer drug market

Since the end of 2022, Pfizer's shares have fallen 42% as the company has repeatedly stumbled with the rapid decline of its COVID business.

Related news